Emavusertib
A small molecule inhibitor used in cancer treatment
Emavusertib | |
---|---|
![]() | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | |
PubChem | |
DrugBank | |
ChemSpider | |
KEGG |
Emavusertib is a small molecule inhibitor that targets specific kinases involved in the regulation of cell growth and survival. It is primarily being investigated for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit | edit source]
Emavusertib functions by inhibiting the activity of certain protein kinases, which are enzymes that modify other proteins by chemically adding phosphate groups. This process, known as phosphorylation, is crucial for the regulation of many cellular processes, including the cell cycle, apoptosis, and signal transduction pathways. By inhibiting these kinases, Emavusertib can disrupt the signaling pathways that promote cancer cell proliferation and survival.
Clinical Development[edit | edit source]
Emavusertib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various types of cancer, including leukemia, lymphoma, and solid tumors. These trials are designed to determine the optimal dosing regimen, assess potential side effects, and evaluate the drug's effectiveness in shrinking tumors or slowing disease progression.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of Emavusertib involves its absorption, distribution, metabolism, and excretion in the body. Understanding these parameters is essential for determining the appropriate dosing schedule and predicting potential drug interactions. Emavusertib is typically administered orally, and its bioavailability, half-life, and metabolic pathways are subjects of ongoing research.
Potential Side Effects[edit | edit source]
As with many cancer therapies, Emavusertib may cause a range of side effects. Commonly reported adverse effects include fatigue, nausea, and hematological abnormalities such as neutropenia and thrombocytopenia. Monitoring and managing these side effects is a critical component of patient care during treatment.
Research and Future Directions[edit | edit source]
Ongoing research is focused on identifying biomarkers that can predict which patients are most likely to benefit from Emavusertib therapy. Additionally, studies are exploring the potential of combining Emavusertib with other therapeutic agents to enhance its efficacy and overcome resistance mechanisms.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD